Haemonetics Corporation (HAE) Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets

Haemonetics Corporation Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets

Haemonetics Corporation (HAE) reported Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets of 0.96% for the 12-month period ending 2026-03-28, per its 10-K filed 2026-05-20.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets · last filed 2026-05-20

• Haemonetics Corporation defined benefit plan, assumptions used calculating net periodic benefit cost, expected long-term rate of return on plan assets for fiscal 2026 was 0.96%, a 9.09% increase from fiscal 2025.
• Haemonetics Corporation defined benefit plan, assumptions used calculating net periodic benefit cost, expected long-term rate of return on plan assets for fiscal 2025 was 0.88%, a 6.38% decline from fiscal 2024.
• Haemonetics Corporation defined benefit plan, assumptions used calculating net periodic benefit cost, expected long-term rate of return on plan assets for fiscal 2024 was 0.94%, a 8.05% increase from fiscal 2023.
• Haemonetics Corporation defined benefit plan, assumptions used calculating net periodic benefit cost, expected long-term rate of return on plan assets for fiscal 2023 was 0.87%, a 26.09% increase from fiscal 2022.